Voyageur Pharmaceuticals (TSXV:VM) ROCE % : -84.33% (As of Feb. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Voyageur Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Voyageur Pharmaceuticals's annualized ROCE % for the quarter that ended in Feb. 2024 was -84.33%.

Voyageur Pharmaceuticals ROCE % Historical Data

The historical data trend for Voyageur Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyageur Pharmaceuticals ROCE % Chart

Voyageur Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

ROCE %

Get a 7-Day Free Trial

-74.40

-193.78

-177.24

-101.68

-93.19

Voyageur Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
ROCE %	Get a 7-Day Free Trial															-79.09	-120.35	-29.15	-68.73	-84.33

Voyageur Pharmaceuticals ROCE % Calculation

Voyageur Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Nov. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Nov. 2023 )		(A: Nov. 2022 )		(A: Nov. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Nov. 2023 )		(A: Nov. 2022 )		(A: Nov. 2023 )
	=	-1.395	/	( ( (2.095 - 0.591)	+	(2.164 - 0.674) )	/ 2 )
	=	-1.395	/	( (1.504	+	1.49)	/ 2 )
	=	-1.395	/	1.497
	=	-93.19 %

Voyageur Pharmaceuticals's ROCE % of for the quarter that ended in Feb. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	-1.316	/	( ( (2.164 - 0.674)	+	(2.562 - 0.931) )	/ 2 )
	=	-1.316	/	( ( 1.49	+	1.631 )	/ 2 )
	=	-1.316	/	1.5605
	=	-84.33 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

Voyageur Pharmaceuticals (TSXV:VM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Voyageur Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Voyageur Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyageur Pharmaceuticals (TSXV:VM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Voyageur Pharmaceuticals Ltd (TSXV:VM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

VYYRF:USA

Address

333 Southwest 7th Avenue, Suite 800, Calgary, AB, CAN, T2P 2Z1

Website

https://www.voyageurpharmaceuticals.ca

Voyageur Pharmaceuticals Ltd is engaged in the development of pharmaceutical ingredients (API) minerals. The company focuses on developing barium and iodine radiocontrast products and bromine-based pharmaceutical products. It provides its products for medical applications and diagnostics.

Voyageur Pharmaceuticals (TSXV:VM) Headlines

No Headlines